The potential and current status of acotinib/acalabrutinib in the treatment of lung cancer

Acalabrutinib/Acalabrutinib is an oral targeted therapy that has received widespread attention. Currently, it is mainly used to treat hematological tumors such as B-cell lymphoma, and has demonstrated significant therapeutic effects. However, regarding the application of acotinib in the treatment of lung cancer, the situation is relatively complicated.

Although acotinib is not officially approved for the treatment of lung cancer, it may have some therapeutic potential in certain groups of lung cancer patients. As a more selective BTK inhibitor than ibrutinib, acotinib is designed to reduce some of the treatment-limiting toxicities associated with ibrutinib, such as atrial fibrillation and bleeding, thereby improving treatment tolerance in patients.

In the field of lung cancer, especially non-small cell lung cancer (NSCLC), EGFR mutation is an important therapeutic target. Currently, a variety of targeted therapeutic drugs targeting EGFR mutations have been approved for the treatment of NSCLC. However, recent studies have shown that acotinib may play a therapeutic role in patients with EGFR mutation-positive NSCLC. These preliminary findings suggest that acotinib may improve the prognosis of these patients by inhibiting tumor growth and spread.

However, it should be emphasized that research on acotinib as a treatment for lung cancer is still in its infancy and has not been officially approved for this purpose. Therefore, for lung cancer patients, when choosing treatment options, they should rely on doctors’ professional advice and the latest clinical research guidelines. In the future, with the accumulation of more clinical data and in-depth research, we are expected to have a more comprehensive understanding of the value and positioning of acotinib in the treatment of lung cancer.